
Lipocine (LPCN) Stock Forecast & Price Target
Lipocine (LPCN) Analyst Ratings
Bulls say
Lipocine Inc. has demonstrated significant advancements in its product pipeline, particularly with LPCN 1154, which presents an improved efficacy and safety profile over zuranolone, evidenced by a 61% remission rate at Day 3 and no adverse events of excessive sedation during clinical trials. The company is on track for a potential New Drug Application (NDA) submission for LPCN 1154 in the U.S. based on favorable topline data, which has increased the probability of approval to 50%. Despite a net loss of $3.2 million, Lipocine's ongoing innovations and strategic developments enhance its growth potential, underscoring a positive outlook for the company's future performance.
Bears say
Lipocine Inc reported a net loss of $3.2 million in the third quarter of 2025, raising concerns about its financial stability as it continues to invest in research and development. The company faces significant risks related to its LPCN 1154 product, including potential failure in clinical trials, the inability to secure regulatory approval, and challenges in achieving commercial success amid competition. Additionally, there is a looming dilution risk, which could further affect shareholder value and investor confidence.
This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.
Lipocine (LPCN) Analyst Forecast & Price Prediction
Start investing in Lipocine (LPCN)
Order type
Buy in
Order amount
Est. shares
0 shares